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Summary.-The principal expression of immunity elicited in syngeneic rats immu-
nized with rat hepatoma membrane fractions was the development of a tumour
specific antibody response. This antibody was demonstrable by membrane immu-
nofluorescence staining of viable hepatoma cells in suspension and the sera exhibited
complement dependent cytotoxicity for cultured hepatoma cells. In the absence of
complement, however, membrane immune sera were highly " blocking ", protecting
plated hepatoma cells from attack by sensitized lymph node cells. The cell mediated
immune response elicited by hepatoma membrane immunization was weak, as
evaluated by the colony inhibitory activity of lymph node cells for hepatoma cells
in vitro or the adoptive transfer of immunity with peritoneal exudate cells. Corre-
lated with this overall pattern of immune response, membrane immunization did
not elicit tumour rejection reactions. These findings are relevant to current views
that humoral factors operate antagonistically to limit cell mediated immunity to
tumours. A further relevant feature was the observation that membrane immuni-
zation, eliciting a prominent humoral immune reaction, conditioned the recipients
so that they subsequently failed to elicit a tumour rejection immunity on treatment
with irradiated tumour cells.
TUMOUR-SPECIFIC antigens expressed
at the cell surface of aminoazo dye
induced rat hepatomata are discrete
components of the plasma membrane and
can be isolated in subcellular membrane
fractions following homogenization of
tumour cells either by intracytoplasmic
cavitation with nitrogen gas (Baldwin and
Moore, 1969a) or by controlled mechanical
rupture under conditions where nuclear
damage isminimized (Baldwin andGlaves,
1972). Furthermore, the membrane asso-
ciated antigen on one hepatoma, D23, has
been solubilized by limited papain diges-
tion of tumour membrane fractions and
subsequent fractionation has yielded an
essentially homogeneous protein with an
approximate molecular weight of 55,000
(Baldwin, Harris and Price, 1973). In all
of these studies, the antigenicity of sub-
cellular fractions of tumour was assayed
by their capacity to absorb antibody from
tumour immune sera, prepared in syn-
geneic rats, this being measured by reduc-
tion ofthe membrane immunofluorescence
staining with viable hepatoma D23 cells
(Baldwin and Moore, 1969a; Baldwin and
Glaves, 1972; Baldwin et al., 1973). The
antigens detected in this manner showed
the same individual tumour specificity as
thetumourrejectionantigensdemonstrable
bytumourtransplantation methods (Bald-
win and Barker, 1967a) and by the cyto-
toxicity ofserum and lymph node cells for
cultured hepatoma cells (Baldwin and
Embleton, 1971), the implication being
that tumour rejection antigens were being
isolated. It was also established that the
methods could be employed to isolate
membrane fractions retaining tumour
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specific antigens from a spontaneously
arising rat mammary carcinoma (Baldwin
and Embleton, 1970) and 3-methylcholan-
threne induced rat sarcomata (Baldwin,
Pimm and Price, to be published) and
again the isolated membrane preparations
expressed antigenic specificities identical
to those demonstrable on intact cells by
tumour rejection assays.
Comparable studies have similarly
established that soluble tumour specific
antigens can be isolated from carcinogen
induced guinea-pig sarcomata (Oettgen
et al., 1968; Holmes, Kahan and Morton,
1970; Suter et al., 1972). Extraction of
tumour with 3 mol/l KCIhas also been used
to solubilize tumour specific antigens asso-
ciated with guinea-pig hepatomata (Melt-
zer et al., 1971) and rat sarcomata (Thom-
son and Alexander, 1973).
These studies draw attention to the
possible use of subcellular tumour frac-
tions for immunotherapy. More impor-
tant, however, is the contribution of
immune responses to tumour cell fractions
in tumour bearing hosts, since recent
studies have established that circulating
tumour specific antigen is detectable in the
serum of rats bearing transplanted hepa-
tomata (Baldwin, Bowen and Price, 1973)
and sarcomata (Thomson, Steele and
Alexander, 1973). In the rat hepatoma
system it has been shown that circulating
tumour antigen can modify the effective
mediation oftumour immunity by inhibit-
ing lymphocyte cytotoxicity whilst
immune complexes may also act at the
level of the effector cells, inhibiting their
cytotoxicity, or blocking target tumour
cells from lymphocyte attack (Baldwin,
Price and Robins, 1972, 1973b).
The objective of the present investiga-
tion was to analyse the cellular and
humoral immune responses to subcellular
fractions of hepatomata in order to ascer-
tain whether these responses will contri-
bute to, or act antagonistically against,
tumour immunity elicited against intact
tumour cells and known to exist also in
tumour bearing rats (Baldwin, Embleton
and Robins., 1973).
MATERIALS AND METHODS
Rats.-Rats of an inbred Wistar strain
were used. These animals accept skin
grafts exchanged between individuals of the
same sex.
Tumours.-Hepatomata were originally
induced by oral administration of4-dimethyl-
aminoazobenzene (DAB), and were carried
as transplant lines in syngeneic rats of the
same sex as the primary host (Baldwin and
Barker, 1967a). Most tests were carried out
with a hepatoma designated D23. Single
cell suspensions were prepared from minced
tissue by repeated treatment with 0.25%
trypsin and deoxyribonuclease. Cell via-
bility was assessed by trypan blue exclusion
and only preparations containing more than
95% viable cells were used.
Isolation of subcellular fractions of tumour
cells-.Tumour cells were homogenized by
nitrogen cavitation at 56 to 70 kg/cm2 for
30 min with continuous stirring (Baldwin and
Moore, 1969a). In early tests, homogeniza-
tion was carried out on cell suspensions in a
sucrose buffer, pH 7*4 (Ozer and Wallach,
1967), but in later experiments minced
tumour tissue was homogenized in a medium
containing NaHCO3 (1 x 10-3mol/l) and
CaCl2 (2 x 10-3 mol/]), pH 7-6. Afterrelease
ofN2gas, EDTAwasaddedtothehomogenate
to give a concentration of 1 x 10-3mol/l,
and nuclei were removed by centrifugation
twice at 600 g for 15 min. A total extra-
nuclear membrane (ENM) fraction was
isolated from the supernatant by centri-
fugation at 105,000 g for 60 min. The
105,000 g supernatant was concentrated by
dialysis against Aquacide (Calbiochem Ltd.,
London, England) to give a soluble " cell
sap " fraction.
A plasma membrane fraction was also
isolated from tumour cells as described by
Baldwin and Moore (1968, 1969b). Cells
were gently stirred for 16 hours at 2°C in
0.9% w/v NaCl. They were harvested by
centrifugation at 600 q for 15 min and
extracted with distilled water to a point short
of cell lysis. Eluted membrane material
was collected from the aqueous extract by
centrifugation at 80,000 g for 30 min.
The protein concentration of subcellular
fractions was assayed by the method of
Lowry et al. (1951).
Immunogenicity tests.-Syngeneic rats of
the appropriate sex were immunized against
extranuclear membrane, plasma membrane
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and soluble cell fractions by repeated intra-
peritoneal injections at weekly intervals.
Rats were challenged subcutaneously 7-14
days after the final injection with known
numbers of tumour cells suspended in
medium 199. The growth of tumours in
immunized rats was compared with that in
untreated controls receiving the same cell
inoculum.
In some experiments rats were immunized
with heavily irradiated (15,000 rad) tumour
cells by 3-8 subcutaneous inoculations at 2-
week intervals (Baldwin and Barker, 1967a).
Adoptive transfer tests.-Immunized and
control rats were injected intraperitoneally
with 3 ml of a 3% w/v suspension of hydro-
lysed starch (Connaught Laboratories,
Toronto, Canada) in phosphate buffered
saline (PBS), pH 7-3. Two days later
peritoneal exudate cells were aspirated in
medium 199 containing heparin (50 i.u./ml).
The cells were washed in 199 and mixed in
vitro in fixed ratios with known numbers of
tumour cells, and the mixtures were immedi-
ately injected subcutaneously into syngeneic
rats. The peritoneal cells were 100% viable
and consisted of about 80% macrophages,
15-18% lymphocytes and a small propor-
of granulocytes.
Immunofluorescence test.-A membrane
immunofluorescence test was employed to
detect tumour specific humoral antibody
in the sera of immunized rats, as previously
described (Baldwin and Barker, 1967b;
Baldwin et at., 1971). A fluorescence index
(FI) was calculated as the proportion of
unstained cells in samples exposed to normal
rat serum, minus the proportion of unstained
cells in the sample exposed to test serum,
divided by the former figure. An Fl of
0 30 or greater represents a statistically
significant positive reaction.
Colony inhibition tests.-Colony inhibition
(CI) tests were carried out to detect lymph
node cell (LNC) mediated immunity and
complement dependent cytotoxic antibody
against hepatoma cells, as described by
Baldwin and Embleton (1971). Target cells
were hepatoma cell lines serially propogated
in vitro as monolayers in Eagle's minimum
essential medium (MEM) supplemented with
calf serum (10%), penicillin (200 i.u./ml) and
streptomycin (100 ,ug/ml).
In addition to studying LNC and antisera
separately, the blocking effect of sera from
ENM immunized rats on colony inhibition
mediated by LNC from rats immunized with
heavily irradiated tumour grafts was exam-
ined. In these tests, target cells (1 to
2 x 103) were plated in 4 ml of medium
into 5 cm plastic petri dishes and incubated
for 24 hours at 37°C. The medium was
removed and replaced by either normal rat
serum or test serum (0.1 ml) diluted with
MEM (0 4 ml). Sera were inactivated at
56°C for 30 min before use. The dishes were
incubated at 37°C for 30 min and the serum
was removed. LNC (5 x 106 cells in 0 5 ml
MEM) from normal or immune rats were
then added, followed by a further 45 min
incubation. MEMcontaining 10% calfserum
(3 5 ml) was added to the LNC in each dish
and the cultures were incubated for 6 days.
The hepatoma cell colonies developing were
fixed in methanol, stained with 1% aqueous
crystal violet and counted. Three to 4
dishes were used for each combination ofLNC
and serum.
The percentage CI in the presence of each
serum was calculated by comparing the
number of colonies formed in dishes treated
with immune LNC with those in dishes
treated with normal LNC. Percent abro-
gation of CI was calculated by comparing
%CI in the presence of test serum with %CI
in the presence of normal rat serum. The
results were evaluated statistically by
Student's t test.
RESULTS
Tumour rejection tests
Experiments in which the capacity
of subcellular fractions of hepatoma D23
to produce immunoprotection in syngeneic
rats against a low-dose (103 cells) chal-
lenge with hepatoma D23 are sum-
marized in Table I. In only one of the 5
experiments with the total extranuclear
membrane fraction (ENM) of hepatoma
D23 was there any protective response to
challenge with hepatoma D23 cells but
these rats failed to reject a second chal-
lenge with 5 X 103 tumour cells. Like-
wise, no protection was produced with a
plasma membrane fraction prepared by
aqueous elution of hepatoma D23 cells,
although both this fraction and the ENM
preparations retain hepatoma D23 specific
antigen, as assayed by their capacity to
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TABLE I. Induction of Immunity to Transplanted Hepatomna D23 By Hepatoma
D23 Cells and Subcellular Fractions
Tumour takes* in
Total dose , A
mg protein Treated Untreatecd
14- 1 4/4 5/5
69- 3 4/4 6/6
70 1 1/6 6/6
94 7 6/6 6/6
181 4 2/3 4/4
18-2 4/4 6-6
18- 1 2/2 3/3
16- 9 5/5 4/4
84- 3 4/4 ,3/4
78- 6 4/4 4/4
42- 6 4/4 5/5
* Challenge inoculum 1 x 103 hepatoma D23 cells.
TABLE II. Effect ofPeritoneal Exudate Cellsfrom Donors Immunized with D23
Extranuclear Membrane Fractions on Growth of Tumour D23 in Normal Syngeneic
Recipients
Immunization of peritoneal
exudate cell donor
mg protein
103-8
119-8
119-8
1198-
Tumour
cell dose
104
104
104
104
104
104
104
104
104
104
Peritoneal
cell dose
4 x 105
4 x 105
106
106
5 x 105
5 x 105
5 x 105
5 x 105
5 x 105
5 x 105
Peritoneal: tumour
cell ratio
40: 1
40: 1
100 : 1
100: 1
50: 1
50: 1
50: 1
50: 1
50: l
50: I
Tumour
takes
5/5
5/5
5/5
5/5
0/4 4/4
4/4 1/4
4/4
4/4
* ENMF: rats immunized with extranuclear membrane fractions.
t IR graft: rats immunized with irradiated grafts of whole tumour tissue.
absorb antibody from syngeneic tumour
immune sera (Baldwin and Moore, 1969a).
The soluble cytoplasmic fraction isolated
from tumour homogenates prepared by
nitrogen pressure homogenization also
did not elicit tumour immunity and this is
consistent with previous studies showing
these fractions to be deficient in tumour
specific antigen, assayed by their capacity
to neutralize tumour specific antibody in
syngeneic antisera, as measured by mem-
brane immunofluorescence tests (Baldwin
and Moore, 1969b). These findings with
subeellular fractions contrast with the
consistent immunogenicity of intact hepa-
toma cells where immunization with
irradiated cells 1-3 times at 2-weekly
intervals provides protection to subse-
quent challenges with up to 5 X 105
viablehepatoma cells (BaldwinandBarker,
1967a).
Cellular and humoral immune responses
to hepatoma D23 subcellularfractions in
syngeneic rats
Cell mediatedimmunity elicitedagainst
hepatoma D23 ENII was assayed by the
capacity of peritoneal exudate (PE) cells
from treated rats to adoptively transfer
resistance (Table II). In agreement with
Immunizing
fraction
Extranuclear
membrane
Plasma
membrane
Cell sap
Number of
injections
1
3
7
9
10
3
6
6
8
3
8
No. injections
5 x ENMF*
None
6 x ENMF
None
4 x IR graftt
6 x ENMF
None
5 x IR graft
6 x ENMF
None
392IMMUNOGENICITY OF RAT HEPATOMA MEMBRANE FRACTIONS
TABLE III. Inhibition of Hepatoma Cell Colony Formation by Lymph .Node Cells
or Serum from ENM Immunized Rats
ENMI treatment of
LNC and serum donors
Target A
cells No. injections AMg protein
D23
D23
D23
D23
D23
D30
D30
D30
D30
D,31
D31
D31
D31
5
6
103-8
119-8
8 204 0
4
5 (D30)§
4
5
5
6
4
5
6
6 (D23)§
78-2
85-3
39-8
19-6
85-3
43-3
46-2
47-6
57-6
119-8
% Colony inhibitiont, I in the presence of
.~~~~~~~~
Lymph node cel
90.5*** 70.1***
79-6*** 8-6
-15-3 45 0
-18-6
-3 9 11-5 -
-3 9 -5-6
6*1
-3-8 5-1 -
-10-8 15.9*
5.9 5.9 1
19.0* 15-4**
-10 *0
1-8
19 - 2
[s Serum
97 0*** 98-5***
-5-8
39 4*** 40- 1***
42 0*** 74 - 5***
7.6 74-5***
72-3** 63-8**
5-2 -3 8
10- 6*
-3-6 14-6
18-2*
4-7
1-3
6-5
2-0
-2-6
14-3*
2-4
15-0**
4 0
5-3
1-7
-10-8
§ colony inhibition = mean reduction of colony numbers in dishes treated with test LNC or serum,
compared with those treated with control LNC or serum.
t Probability that % colony inhibition values are due to chance is indicate(d by: * P < 0 05 ** P < 0- 01
***P < 0-001.
I Rats treated with ENMI from a tumour different from the target cells.
a previous study (Baldwin and Barker,
1967b) peritoneal exudate cells from rats
immunized against hepatoma D23 sup-
pressed tumour growth in all but one rat
when injected in ratios of 50/tumour cell.
Peritoneal exudate cells from ENM
treated rats at doses up to 100 PE cells/
tumour cell were completely ineffective,
so that tumours developed in all treated
rats and at rates comparable with those
in rats receiving PE cells from normal
animals.
Cellular immunity elicited by hepa-
toma D23 ENM preparations was also
examined in vitro by the capacity of
lymph node cells (LNC) from treated
rats in comparison with LNC from
untreated controls to inhibit colony for-
mation of plated hepatoma D23 cells
(Table III). Of the 13 preparations
tested, only 3 produced significant inhi-
bition of colony formation so that the LNC
mediated response to hepatoma D23 ENM
was much less consistent than that elicited
by intact cells (Baldwin and Embleton,
1971). It is notable, however, that in
the 3 positive tests the LNC exerted a
pronounced inhibitory effect, producing
colony inhibition indices of 70-1-90.5%.
ENM preparations from 2 other hepa-
tomata, D30 and D31, were also examined
for their capacity to elicit the formation
of sensitized LNC which inhibit colony
formation by cells of the homologous
tumour (Table III). Only 4/10 of the
tests with LNC from hepatoma D30 ENM
treated rats and 1/6 tests with hepatoma
D31 ENM treated rats produced signifi-
cant inhibition of colony formation.
Moreover, these reactions were much
weaker in terms of the percentage colony
inhibition compared with the reactivity
of LNC from rats immunized against
intact hepatoma cells (Baldwin and Emble-
ton, 1971).
Humoral antibody
Tumour specific antibody elicited
against hepatoma D23 subcellular frac-
tions was assayed by the capacity of sera
from treated rats to react in immuno-
fluorescence tests with cell membrane
expressed antigen on viable hepatoma
35-6**
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TABLE IV.-Humoral Antibody Response Evoked by Cells and Subcellular
Fractions ofHepatoma D23
Hepatoma*
fraction
Whole cells
Whole cells
Extranuclear
membrane
Extranuclear
membrane
Extranuclear
membrane
Extranuclear
membrane
Extranuclear
membrane
Extranuclear
membrane
Plasma membrane
Plasma membrane
Plasma membrane
Plasma membrane
Plasma membrane
Soluble
Soluble
No. of
injections
3
8
1
3
7
3
5
3
4
8
6
6
3
3
8
Total immunizing
dose (mg protein)
Graft
Graft
14*1
40 0
70-1
40* 0
110-5
69-3
56-9
84-3
16-9
18-1
18-2
78-6
42 6
Fluorescence indext against
D23 cells
0 37, 0-48, 0 53, 0 45
0-68, 0 50
0-02, 0, 0-08, 0-01, 0*32, 0*07
0*43, 0-24, 0-66, 0-37, 0-48
0*53, 0-32, 0 37, 0*72, 0 30
0 30, 0-26, 0-63, 0-63, 0-52
0-48, 0*39, 0-68, 0*59, 0 59
0 53, 0 55
0 70, 0-38, 0 75, 0.81
0-81, 0 79, 0*72, 0-65, 0 73
0*46, 0-72, 0 46, 0-36
0*14, 0 04, 0, 0, 0-10, 0*16
0 04, 0*15
* Whole cells received 15,000 rad 60Co y-irradiation.
t A fluorescence index of 0 30 or greater represents a positive reaction.
D23 cells in suspension (Table IV).
Both types of hepatoma D23 membrane
preparation (ENM and.plasma membrane)
elicited good tumour specific antibody
responses, fluorescence indices of between
0 30 and 0-81 being obtained with anti-
sera. Predictably, a single immunization
with ENM did not elicit detectable levels
of tumour specific antibody but it is
significant that where multiple doses of
either preparation were administered,
even small amounts (16 9 mg protein) of
membrane produced sera with fluorescence
indices even higher than those observed
with sera from rats immunized against
irradiated tumour cells or by excision of
tumour grafts and multiple challenges
with viable tumour cells (Baldwin and
Barker, 1967b; Baldwin et al., 1971).
These qualitative data therefore indicate
that the hepatoma D23 membrane pre-
parations are as good as, or even more
effective than, intact cells in eliciting
tumour specific antibody responses in
syngeneic rats. In contrast, the cyto-
plasmic fraction which is considered to be
lacking in tumour specific antigen (Bald-
win and Moore, 1969a) did not induce
antibody responses detectable by mem-
brane immunofluorescence staining of
viable hepatoma D23 cells (Table IV).
Antibody elicited against hepatoma
D23 ENM was also demonstrated by the
complement dependent cytotoxicity of
sera from treated rats for plated hepatoma
D23 cells (Table III). In this case the
expression of cytotoxic antibody (10/11
tests positive, CI 35.6-98.5%) was a much
more frequent event than the develop-
ment of cytotoxic sensitized LNC. The
formation of tumour specific antibody
appeared to be a specific feature of hepa-
toma D23 ENM since in tests with ENM
preparations from hepatoma D30 and D31
only 2/13 sera were cytotoxic for cells of
thehomologous tumour (CI 15.0andl4. 3%
respectively).
Blocking of lymph node cell cytotoxicityfor
hepatoma cells by rat antisera qgainst
tumour ENMfractions
Tests were carried out to evaluate
whether sera prepared by treating rats
with ENM fractions from hepatomata
Expt
No.
IA
2B
2A
2B
2C
2D
2E
3A
3B
3C
3D
4A
4B
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TABLE V.-Abrogation of Cell Mediated Inhibition ofHepatoma Cell Colony
Formation by Serafrom ENM Immunized Rats
Immunization of
LNC donor*
3 IR + 3 ch
3 IR + 3 ch
3 IR + 3 ch
3 IR + 3 ch
4 IR + 2 ch
4IR + 2 ch
4 IR + 8 ch
4 IR + 8 ch
3 IR + 6 ch
3 IR + 6 ch
3 IR + 3 ch
3 IR + 3 ch
3 IR + 3 ch
3 IR + 8 ch
3 IR + 8 ch
3 IR + 8 ch
4 IR + 2 ch
4 IR + 2 ch
14 days post-exc.
14 days post-exc.
14 days post-exc.
21 days post-exc.
21 days post-exc.
21 days post-exc.
21 days post-exc.
ENM treatn
serum do
No. injections
None
6
6
5 (D30)
None
5
None
8
None
8
None
4
5
None
4
5
None
4
None
6
4 (D31)
None
4
5
4 (D30)
aent of
nor
Mg protein
None
119-8
119-8
85-3
None
103-8
None
204
None
204
None
39-8
29-6
None
46-2
47-6
None
46 2
None
35 0
46 2
None
46-2
46-2
39-8
* IR = treatment with irradiated (15,000 rad 60Co y-irradiation) tumour grafts; ch = challenge with
viable hepatoma cells; post-exc. = removal of growing tumour by surgical excision.
t % colony inhibition = % reduction of colony numbers in dishes treated with immune LNC, compared with those treated with control LNC.
t % abrogation = % reduction of LNC mediated colony inhibition in dishes treated with test serum
compared with % colony inhibition in those treated with control serum.
D23, D30 and D31 could specifically
protect the homologous target tumour
cells from the cytotoxic action of sensi-
tized lymph node cells (Table V). The
sensitized LNC used in each test were
from rats immunized by repeated implan-
tation of irradiated tumour followed by a
series (2-8) of challenges with viable
tumour cells. In the case of hepatomata
D30 and D31 LNC were also taken from
rats 14 and 21 days respectively after
excision of hepatoma grafts. In the tests
with hepatoma D23, pretreatment of
plated tumour cells with normal serum
did not abolish their susceptibility to
hepatoma D23 sensitized lymph node
cells and in each of the 4 tests significant
inhibitionofcolonyformationwasobtained
(CI 18-6-66.7%). In the first experi-
ment pretreatment of plated hepatoma
D23 cells with D23 ENM immune sera
reduced the CI from 66.7% to 6-1 and
2* 1% respectively, this representing 90 7-
96.7% abrogation of LNC cytotoxicity.
In contrast, treatment with hepatoma
D30 ENM antiserum had no effect so that
the colony inhibition was slightly greater
(72.4%) than that observed with cells
treated with normal serum. This is
consistent with the known immunological
specificities of the tumour antigens asso-
ciated with these hepatomata and indi-
cates that the blocking action of ENM
antisera is a specific event.
Pretreatment of plated tumour cells
with sera from rats immunized against
ENM preparations of hepatoma D30 and
D31 also specifically inhibited the cyto-
toxicity of sensitized LNC. In tests with
hepatoma D30 pretreatment of plated
hepatoma cells with 3 different sera from
rats immunized with ENM fractions ofthe
Target
cells
D23
D23
D23
D23
D23
D23
D23
D23
D23
D23
D30
D30
D30
D31
D31
D31
D31
D31
D30
D30
D30
D31
D31
D31
D31
% Colonyt
Inhibition
66-7
6-1
2-1
72-4
35-9
17-2
18 6
0
21*5
9 9
20-3
13-2
10-4
46-1
-21 3
-13-9
16-9
-7-4
29-7
-12-6
20-7
26-9
0
2 0
37-2
P <
0-001
0 30
0 35
0 005
0 005
0 05
0 005
0 05
0 05
0-25
0-20
0 05
0 05
0 05
0 05
0-01
0 475
0.01
%T
Abrogation
90 7
96 7
-9-2
52 1
100
53.9
34-7
48-7
100-0
100.0
100.0
100-0
30- 4
100-0
92-6
-38-4
0-001
0-001
0 05
0 05
0 20
0*20
0-20
0*05 0 05
0.01
0-05
0-45
0-001
0-01
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TABLE VI.-Irnpairment of Host Resistance to Hepatoma D23 by Pretreatment of
Rats with Hepatoma D23 Membrane
D23 membrane pretreatment
No. of
injections Mg protein
6 52-3
6 52-3
None
5
5
None
69- 7
69-7
Immunizing
tissue
Normal liver
D23
D23
Normal liver
D33
D33
No. of
IR* grafts
2
2
2 2
2
2
Challenge
tumour
D23
D23
D23
D33
D33
D33
No. of
cells
103
103
103
2 x 104
2 x 104
2 x 104
Challenge takes in:
( - -
Treated
rats Controls
5/5 6/6
4/5 6/6
0/5 6/6
4/4 4/4
0/5 5/5
1/5 5/5
* IR: Irradiated tumour graft (15,000 rad) 60Co y-irradiation.
homologous tumour reduced LNC medi-
ated colony inhibition to an insignificant
level. These tests included a cross test
in which plated hepatoma D30 cells were
treated with serum from rats immunized
with D31 ENM but this did not produce
significant blocking. All of the sera
prepared against hepatoma D31 fractions
were highly effective in blocking the cyto-
toxicity of sensitized LNC for plated
hepatoma D31 cells. In one experiment
2 sera against hepatoma D31 ENM
produced 100%0 and 92 6Oo blocking ofD331
sensitized LNC cytotoxicity, whereas sera
from D30 ENM immunized rats were
without effect.
Impairment of host resistance to hepatoma
D23 following pretreatment of rats with
hepatoma D23 membrane
These experiments were designed to
ascertain whether immunization against
hepatoma D23 ENM, which preferentially
elicits a humoral immune response, would
modify the tumour rejection response
elicited by irradiated hepatoma cells.
(Table VI). Rats pretreated with hepa-
toma D23 ENM, and subsequently
immunized with irradiated hepatoma
D23 grafts, were not able to reject a
challenge with hepatoma D23 cells which
developed into progressively growing
tumours in all recipients. Likewise, im-
munization with D23 ENM followed
by irradiated normal liver failed to
induce any immunity against hepatoma
D23. Control rats receiving only irradi-
ated hepatoma D23 cells all elicited a
specific resistance against hepatoma D23
cells. The second experiment was carried
out as a specificity control and in this
case an initial immunization with hepa-
toma D23 ENM did not influence subse-
quent immunization with irradiated grafts
of hepatoma D33.
DISCUSSION
The principal expression of immunity
elicited in syngeneic rats by hepatoma
membrane fraction was the development
of a humoral antibody response, demon-
strable by membrane immunofluorescence
staining of viable hepatoma cells, and by
complement dependent cytotoxicity of
the sera for plated hepatoma cells,
resulting in a significant inhibition of
colony formation. The cell mediated
immune response, on the other hand, was
generally weak so that lymph node cells
from membrane immunized rats did not
consistently produce a significant inhibi-
tion of colony formation by plated hepa-
toma cells. Also, peritoneal exudate cells
from these rats were uniformly ineffective
in adoptively transferring immunity to
normal rats.
Correlated with the overall immune
response elicited by hepatoma D23 mem-
brane immunization, in which cellular
immunity was not a prominent feature,
was a failure of treated rats to reject
challenge with threshold doses (1 X 103)
of viable hepatoma cells. This contrasts
with reproducible induction of tumour
resistance following excision of hepatoma
grafts; rats treated in this manner reject-
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ing up to 500-fold larger challenge with
hepatoma cells (Baldwin and Barker,
1967a). With this form of immunization
there is an effective cell mediated immune
response so that lymph node cells taken
from rats post-excision inhibit colony
formation, or cell survival as assayed by
the microcytotoxicity test (Baldwin et al.,
1973b). Cytotoxic antibodyis alsodemon-
strable in post-excision sera, but these
sera do not show positive immunofluores-
cence staining with viable hepatoma cells.
Rats immunized by repeated implantation
of 60Co y-irradiated hepatoma also speci-
fically reject subsequent challenges with
cells of the same tumour. This form of
immunization again provokes a significant
cellular immune reaction and in this case,
tumour-specific antibody is demonstrable
both by serum cytotoxicity and mem-
brane immunofluorescence reactions (Bald-
win and Barker, 1967b; Baldwin and
Embleton, 1971; Baldwin et al., 1973).
The failure of hepatoma membrane
immunization to evoke tumour rejection
reactions, therefore, appears to be asso-
ciated with an immune deviation favour-
ing the formation of tumour specific
antibody. This is further emphasized by
thefindingthat serumfromratsimmunized
with hepatoma membrane specifically
blockshepatomacellsinvitrofromcytotoxic
attack by lymph node cells from tumour
immune donors. Even more important
than this effect at the efferent level was
the observation that prior immunization
with hepatoma D23 membrane specifically
impairs the capacity of rats to elicit a
tumour rejection response on subsequent
immunization with irradiated tumour,
pointing to a regulatory effect on the
lymphoid system.
These observations are pertinent in
respect of current developments, suggest-
ing that interference by circulating
humoral factors, including tumour antigen,
antibody and immune complexes, on cell
mediated immunity is of paramount
importance in the outcome of a tumour
immune response (Baldwin et al., 1972,
1973b). Sera from rats bearing trans-
28
plants of hepatoma D23, for example,
specifically block hepatoma D23 cells in
vitro from attack by sensitized lymph
node cells. These sera will also directly
inhibit the reactivity of lymph node cells
so that preincubation of serum with
effector cells for a short period, and subse-
quent washing, reduce their cytotoxicity
in vitro for hepatoma D23 cells (Baldwin
et al., 1973a). Blocking at the level ofthe
target cells, it is postulated, is mediated
by tumour specific immune complexes
since these sera have been shown to con-
tain such factors in a region of antigen
excess (Baldwin et al., 1973). Moreover,
the blocking effect of immune complexes
has been established in model studies using
complexes prepared by addition of papain
solubilized hepatoma D23 antigen and
post-excision sera as a source of tumour
specific antibody (Baldwin et al., 1972).
Direct inhibition of lymphocyte reactivity
can be effected by solubilized hepatoma
D23 antigen (Baldwin et al., 1973b) so
thattheeffect observedwith tumourbearer
ser-um may also be induced by circulating
antigen or immune complexes. When
these humoral factors are analysed in
relation to tumour status, it is found that
following surgical removal of tumour the
serum factors producing tumour cell
blocking and lymphocyte inhibition are
rapidly lost, and at this stage tumour
specific cytotoxicity antibody becomes
demonstrable (Baldwin et al., 1973). On
subsequent repeatedimmunization,tumour
immune sera continue to demonstrate
complement dependent cytotoxicity and
antibody is demonstrable by membrane
immunofluorescence. At this stage these
antisera, in the absence of complement
show blocking activity, protecting hepa-
toma cells in vitro from sensitized lymph
node cells, but do not directly inhibit
lymph node cell reactivity (Baldwin et al.,
1973a, b). Within this context, antibody
elicited by hepatoma D23 membrane
may act directly as " blocking antibody ",
protecting hepatoma D23 cells from
lymphocyte attack. Even though anti-
body is present in excess, immune com-
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plexes may also be present, resulting from
binding with solubilized hepatoma D23
antigen released from the immunizing
inoculum. This may explain why anti-
body was not regularly demonstrable in
sera from rats immunized with hepatomata
D30 and D31 membrane although the
sera consistently blocked tumour cells
from attack by sensitized lymph node
cells. The release of antigen into the
circulation from the immunizing mem-
brane may also produce an inhibition of
the lymphocyte response. This may be
effected by tumour antigen inhibition of
stimulated lymphocytes, as demonstrated
in model studies showing that the cyto-
toxicity of lymph node cells from hepa-
toma D23 immune rats can be totally
inhibited by addition ofpapain solubilized
antigen (Baldwin et al., 1973b). Addi-
tionally, circulating tumour antigen may
act to inhibit the production of sensitized
lymphocytes in a manner analogous to the
observed lymphocyte anergy in local
nodes draining a tumour (Alexander et
al., 1969).
These studies with transplanted rat
hepatomata indicate the limitations of
using antigenically active subcellular
tumour fractions for tumour immuniza-
tion. Comparably, it has been established
that immunization with membrane frac-
tions from 3-methylcholanthrene induced
sarcomata and a spontaneous mammary
carcinoma (Baldwin and Embleton, 1970;
Baldwin, Pimm and Price, to be published)
does not result in the development of a
tumour rejection reaction. It cannot be
generalized from these studies, however,
that tumour fractions cannot be used to
induce tumour immunity since, for
example, injection of soluble extracts of
guinea-pig sarcomata induced a degree of
resistance comparable with that obtained
with intact cells (Holmes et al., 1970;
Suter et al., 1972). The conditions govern-
ing the type of response elicited against
different tumours in a variety of species
have yet to be defined but one important
condition is likely to be the degree of
stability of the tumour antigen within the
cell membrane. The present observa-
tions are also pertinent to studies now in
progress attempting to utilize immunosti-
mulants such as B.C.G. for immuno-
therapy. For example, with Moloney
sarcomata in the rat, B.C.G. immuno-
stimulation before, or at the time of,
tumour transplantation produces animmu-
noprotective response, whereas when given
2 weeks after, tumour enhancement is
obtained (Bansal and Sjogren, 1973).
Under the latter condition it is highly
probable that in addition to the local
tumour mass soluble or particulate tumour
antigen will be present in the circulation
and from the rat hepatoma studies
reported here, the type of immune res-
ponse will be different from that arising
where only local tumour is present, favour-
ing a humoral antibody response.
Although this has not been analysed in
depth, one consequence of B.C.G. in rats
bearing established Moloney sarcomata
is an increase in serum blocking factors,
which is consistent with the findings from
the present studies with rat hepatomata
showing enhanced antibody levels.
This work was supported by the
Cancer Research Campaign.
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